REVIEW ARTICLE

Topical pine tar: History, properties and use as a treatment for common skin conditions

Tanya M Barnes and Kerryn A Greive
Ego Pharmaceuticals, Braeside, Victoria, Australia

ABSTRACT
Pine tar is the end product of pine wood carbonisation following distillation using extreme heat. An extensive literature search was conducted back to the 1950s for this review. Pine tar has been used in medicine for more than 2000 years to treat a range of skin conditions because of its soothing and antiseptic properties. Pine tar should not be confused with coal tar, which has been produced from coal for approximately a hundred years. Pine tar is thought to exert its effect by reducing DNA synthesis and mitotic activity, which promotes a return to normal keratinisation. In addition, pine tar has been shown to be antipruritic, anti-inflammatory, antibacterial and antifungal. These properties make pine tar suitable for the topical treatment of eczema, psoriasis, seborrhoeic dermatitis and other dry, itchy, flaky or inflamed skin conditions. Topical products available over-the-counter in Australia today contain up to 2.3% pine tar, and come in several different formulations that can be used on the entire body, including the face. Modern day pine tar is manufactured with increased purity to eliminate toxic phenol and carcinogenic components, which have been of concern in the past. Primary irritation is uncommon. In conclusion, the long experience with topical pine tar therapy and its worldwide usage, together with the evidence presented in this review, suggests that pine tar is an effective treatment with minimal safety risk.

Key words: coal tar, eczema, pine tar, psoriasis, seborrhoeic dermatitis.

HISTORY
Tar from pine wood has probably been produced in Scandinavia since the Iron Age. It became one of Sweden’s most important exports for hundreds of years as a preservative for wood exposed to harsh conditions, including ship deckings and rigging. Maritime use spread from Sweden throughout Europe, and eventually to the British Colonies in America, which had extensive pine forests. It is still used today to treat wooden furniture exposed to the elements, as a flavouring for candies, food and alcohol, and on the handles of baseball bats to improve grip.

Pine tar was also known in ancient Greece. In fact, the use of pine tar in medicine was first described by Hippocrates more than 2000 years ago. Pine tar made in villages in Turkey according to traditional methods is still used today for medicinal purposes. Commercial topical pine tar products have been manufactured around the world for well over a hundred years, and have been used for a range of skin ailments including eczema and psoriasis. It may also be present in deodorants, shampoos, tooth-powder and disinfectants.

Topical pine tar has been available over-the-counter in Australia since 1955. Today, it is available in various formulations including a gel, lotion, oil, soap-free bar and solution containing up to 2.3% w/w pine tar (Table 1). Furthermore, pine tar is widely used in veterinary medicine. It is a traditional antiseptic and hoof care product for horses and cattle and is also used to prevent chickens pecking the low hen.

PRODUCTION AND CHEMICAL PROPERTIES
Four sources of tar have been used for therapeutic treatments; wood (wood tar), bitumen (shale tar), petroleum (petroleum tar) and coal (coal tar). There are two kinds of wood tars; made either from trees with a high content of resin (pine and juniper), or from hardwood trees (birch and beech). Pine tar (also known as tar, alquitrán vegetal, pix liquida, stockholm tar (in commerce), wood

Correspondence: Dr Kerryn A Greive, Ego Pharmaceuticals Pty Ltd, 21-31 Malcolm Road, Braeside, Vic. 5195, Australia. Email: kerryng@egopharm.com
Tanya M. Barnes, PhD. Kerryn A. Greive, PhD.
Conflict of interest: Tanya Barnes and Kerryn Greive are employed by Ego Pharmaceuticals, who manufactures pine tar products.
Submitted 3 September 2015; accepted 25 October 2015.

Abbreviations:
CHO Chinese hamster ovary
PAH polycyclic aromatic hydrocarbon

© 2016 The Authors. Australasian Journal of Dermatology © 2016 The Australasian College of Dermatologists.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Topical pine tar

Table 1  Products containing pine tar (without coal tar) available in Australia today, their indications and directions for use

| Pine tar product                        | Indications                                                                 | Directions for use                                                                 |
|-----------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| 0.1% w/w pine tar lotion                | Pruritus (anal and genital), pruritus and inflammation associated with dermatitis, eczema, heat rash, hives, nappy rash, chickenpox, insect bites, and sunburn | May be used as often as required, especially after bathing, showering, shaving (underarms and legs) and at night |
| (Key Pharmaceuticals Macquarie Park, NSW, Australia) |                                                                            | Wet skin, lather bar and apply to affected area. Rinse thoroughly, pat skin dry. Do not rub |
| 1% w/w pine tar bar                     | Pruritus (anal and genital), generalised pruritus and inflammation associated with psoriasis, dermatitis, eczema, urticaria, sunburn, insect bites, heat rash, nappy rash and chickenpox | Apply to wet skin and smooth gently over the affected area. Leave on for 2 to 3 min, rinse lightly, then pat dry. Do not rub. May be used on sensitive areas of the skin such as the face, mucous membranes, anal or vulval area and hands. Use as often as required at the hand basin or in the bath or shower whenever inflamed hands or other areas are washed, particularly at night for very itchy areas. For severe conditions, further therapeutic effect is obtained by soaking in a bath containing pine tar solution or oil. Bath: add 15–50 mL to a tepid bath (5 mL to a baby bath or hand basin) and bathe for 10 min once daily; shower: apply undiluted to wet skin for a few min, then rinse; sponge bath: add 10 mL to 5L warm water. Pat skin dry |
| (Ego Pharmaceuticals Braeside, Victoria, Australia) |                                                                            | Bath (maximum therapeutic effect): add 15–50 mL to a tepid bath (5 mL to a baby bath or hand basin) and bathe for 5–10 min once daily or more often in severe cases; shower: spray approximately 5 mL onto wet skin, leave for a few min, rinse briefly with tepid water; patients in bed: for elderly and surgical patients or those with measles or chickenpox add 10 mL in 2L of warm water and sponge freely; face or other small areas: 10 mL in 2 L cool or iced water. Saturate cotton wool and hold onto affected area for a few min. Repeat for 10 min and pat skin dry; foot, leg or arm bath: the affected area may be soaked separately if preferred. Add 10 mL to 2L tepid water and bathe for 10 min, pat skin dry |
| 1.6% w/w pine tar gel                   | Pruritus (anal and genital), generalised pruritus and inflammation associated with psoriasis, dermatitis, eczema, urticaria, sunburn, insect bites, industrial contact dermatitis, shaving rash and intertriginous inflammation (particularly of the groin area) |                                                                                   |
| (Ego Pharmaceuticals)                  |                                                                            |                                                                                   |
| 2.3% w/w pine tar oil                  | Eczema, dermatitis (allergic and contact), psoriasis, sunburn, and other dry, itchy and inflamed skin conditions | Bath: add 15–50 mL to a tepid bath (5 mL to a baby bath or hand basin) and bathe for 10 min once daily; shower: apply undiluted to wet skin for a few min, then rinse; sponge bath: add 10 mL to 5L warm water. Pat skin dry |
| (Ego Pharmaceuticals)                  |                                                                            | Bath: add 15–50 mL to a tepid bath (5 mL to a baby bath or hand basin) and bathe for 10 min once daily or more often in severe cases; shower: spray approximately 5 mL onto wet skin, leave for a few min, rinse briefly with tepid water; patients in bed: for elderly and surgical patients or those with measles or chickenpox add 10 mL in 2L of warm water and sponge freely; face or other small areas: 10 mL in 2 L cool or iced water. Saturate cotton wool and hold onto affected area for a few min. Repeat for 10 min and pat skin dry; foot, leg or arm bath: the affected area may be soaked separately if preferred. Add 10 mL to 2L tepid water and bathe for 10 min, pat skin dry |
| 2.3% w/w pine tar solution             | Pruritus (anal and genital) and generalised pruritus and inflammation associated with psoriasis, dermatitis, eczema, urticaria, sunburn, insect bites, heat rash, nappy rash and chickenpox |                                                                                   |
| (Ego Pharmaceuticals)                  |                                                                            |                                                                                   |
|                                                                                       | |                                                                                   |

 TAR, brea de pino, brea vegetal, goudron végétal, nadelpulver, pinie bleeddruif, pix abietinarum, pix pini and pyroleum pini). This process causes tar and pitch to drip away from the pine wood leaving behind charcoal. Pine tar is a dark brown or nearly black viscous semi-liquid, which is denser than water and has a characteristic empyreumatic odour and a sharp taste. Pine tar is slightly soluble in water and soluble in alcohol, chloroform, ether, acetone, glacial acetic acid, in fixed and volatile oils and in solutions of caustic alkali. The aqueous liquid produced by shaking pine tar with water is acidic, distinguishing it from coal tar, which is alkaline. The components of pine tar vary according to the pyrolytic process (e.g. method, duration, temperature) and origin of the wood (e.g. the age of the pine trees, type of soil, moisture conditions during tree growth). It is extremely complex, containing several thousand chemical components, primarily aromatic hydrocarbons, tar acids and tar bases. The principal constituents of pine tar include terpineol, resin, guaiacol, cresol, methylecresol, phenol, phlorol, toluene, xylene and other hydrocarbons. The pine tar used in topical products available in Australia today is produced by the traditional method of burning pine tree stumps in kilns. Kiln burned pine tar is dark golden in colour and is characterised by a high resin content (rosin acids and retene), low content of pitch and high purity, and it is free from soot and other impurities. 

MECHANISMS OF ACTION

Although pine tar has been used for the treatment of various skin diseases for thousands of years, its mechanism of action is poorly understood and has been extrapolated from studies performed using coal tar. Pine tar is not pharmacologically standardised because of its inherent chemical complexity, and the specific therapeutic activity of the components is not known.

© 2016 The Authors. Australasian Journal of Dermatology © 2016 The Australasian College of Dermatologists.
Antiproliferative effect

The antiproliferative effect of tars has been studied using coal tar. However, it is postulated that all tars, including pine tar, work in a similar manner. Studies by Lavker and colleagues in volunteers with healthy skin demonstrated a transient increase in epidermal proliferation during the first 2 weeks of tar treatment, followed by a progressive thinning of the epidermis. Tars appear to act as keratolytic agents which inhibit excessive proliferation of epidermal cells by the suppression of DNA synthesis in hyperplastic skin, which subsequently reduces mitotic activity and protein synthesis in the basal layer of the epidermis. This promotes a return to normal keratinisation, which is important in skin diseases such as psoriasis.

Other effects

In addition to its keratolytic action, pine tar has been shown to be antipruritic, anti-inflammatory, anti-septic, astringent, keratoplastic, cytostatic, antimicrobial and antifungal. Fractionation of pine tar has revealed that the components responsible for its bacteriostatic properties are the resin acids, and that acetovanillone, 1,1',3',3'-tetraoxo-2,2'-bicyclopentyl and its 4-methyl derivative, as well as another unknown compound, are responsible for the antifungal properties of pine tar. This is in contrast to coal tar where it is generally considered that phenols are responsible for its biological activity.

In terms of pharmacokinetics, it has been observed by infrared spectroscopy that pine tar is detectable in the skin 1 h following the topical application of 12% pine tar to the skin, but was undetectable in the skin after 8 h. The mechanisms by which pine tar is absorbed, metabolised and excreted are unknown.

CLINICAL USE

Indications

Pine tar has been used in topical preparations to relieve itching and inflammation associated with a range of skin conditions such as eczema or dermatitis, psoriasis, chronic lichen simplex, seborrhoeic dermatitis and scalp psoriasis, sunburn, nappy rash, prickly heat, hives, chicken pox, insect bites, anal and genital itching including jock itch, and other dry, itchy, flaky or inflamed skin conditions.

Contraindications

Sensitivity to pine tar. Pre-existing folliculitis or severe acne are also possible contraindications.

Caution

Avoid contact with eyes. If lather enters eyes, flush with clean water.

How to use

The use of pine tar products available in Australia today is described in Table 1. Pine tar products may be used on the entire body, including the face, as an adjunct cleanser for red, itchy and inflamed conditions together with other prescribed medications such as corticosteroids and fungal creams. Pine tar products are interchangeable, with the oil being particularly useful for widespread dry, red, itchy and inflamed conditions as it is moisturising and suitable for bath use. Similarly, the solution, which is also suitable for bath use, is useful for widespread conditions that are not specifically dry. The bar and gel can both be used in the shower or at the hand basin, with the gel being more elegant to use and the bar suitable for patients who like to be able to hold the product.

As well as pine tar lotion, which contains a very low concentration of 0.1% pine tar, the pine tar formulations described in Table 1 are designed as wash-off products that are quick and easy to use, are less messy than other tar products which need to be left on for many hours, do not stain and any odour is minimised. These attributes may increase patients’ compliance.

PHARMATOXICOLOGY

Toxicity

The acute toxic potential of topical tar products, particularly wood tars, which include pine tar, has been linked to their phenol content. However, since the phenol content has been reduced in the topical pine tar products manufactured today, phenol poisoning is unlikely. In addition, unlike coal tar, which has been shown to be phototoxic, wood tars including pine tar have not been reported to cause photosensitisation.

Carcinogenicity

A more serious problem than toxicity is the potential carcinogenicity of tars, including pine tar, which has often raised safety issues over its use in therapeutic treatments. Carcinogenicity studies in animals have shown that the carcinogenic potential of tars is linked to the polycyclic aromatic hydrocarbon (PAH) fractions. Swallow and Curtis measured the levels of eight different PAH which have been shown to be carcinogenic to animals in six different coal tar solutions commercially available in New Zealand. A commercial product containing only pine tar (Ego Pharmaceuticals Pty Ltd, Braeside, Victoria, Australia) was also included in the study for comparison. The pine tar product was found to contain no detectable levels of four of the eight PAHs studied, and minimum detectable levels of the remaining four PAHs (Table 2). The PAHs present in in the pine tar product summed to 8 mg/kg, which was at least sixfold, and up to approximately 500-fold less than the levels of PAHs in the other commercial coal tar preparations. Variations in PAHs levels were not due solely to the difference in the amount of tar added to the preparation.
Table 2 Polycyclic aromatic hydrocarbon (PAH) concentrations found in topical tar products. Reproduced from Swallow and Cur
tis.21

| Product                 | BA/C | BF | BeP | BaP | Pe | DPHA | DHA | BP | BA/C | BF | BeP | BaP | Pe | DPHA | DHA | BP |
|-------------------------|------|----|-----|-----|----|------|-----|----|------|----|-----|-----|----|------|-----|----|
| HSF solution of coal tar B.P. | 1180 | 580 | 80  | 500 | 35 | 35  | 90  | 60 | 180  | 35 | 35  | 60  | 90 | 60   | 60  | 90 |
| Balnetar bath oil       | 660  | 590 | 180 | 360 | 90 | 60  | 240 | 180| 380  | 10 | –   | –   | –  | 60   | 60  | 90 |
| Alphosyl lotion         | 90   | 10  | 55  | 5   | 6  | 1   | 1   | 5  | 3    | 6  | 1   | 1   | 5  | 4    |     |    |
| Tarquinor skin cream    | 200  | 140 | 60  | 90  | 30 | 10  | 60  | 50 | 200  | 10 | 3   | 6   | 1  | 1    | 5   | 4  |
| Egospsorl TA skin cream | 30   | 15  | 5   | 10  | –  | –   | –   | 5  | 3    |     |     |     |    |     |     |    |
| Polytar scalp cleanser  | 20   | 10  | 3   | 6   | 1  | 1   | 1   | 5  | 4    |     |     |     |    |     |     |    |
| Pinetarsol†             | 2    | 5   | 1   | 2   | –  | –   | –   | –  | –    |     |     |     |    |     |     |    |

†Products available in Australia today. All products contain coal tar except Pinetarsol, which contains pine tar alone. Concentrations are expressed in mg/kg. –, concentrations that are not quantified; that is, below 0.5 mg/kg. BaP, benzo(a)pyrene; BA/C, benzo(a)anthracene and chrysene; BeP, benzo(e)pyrene; BF, benzo(b)fluoranthene, benzo(k)fluoranthene and benzo(j)fluoranthene; DPHA, dibenz(a,j)anthracene; DHA, indeno(1,2,3-cd)pyrene and dibenz(a,h)anthracene; BPe, benzo(ghi)perylene; Pe, perylene.

A study by Athanasiou and Lillis found an absence of mutagenic action of pine tar resin in the Salmonella/microsomal cell culture system as developed by Ames and colleagues, and an absence of clastogenic action in Chinese hamster ovary (CHO) cell culture.22,23 Thus it can reasonably be assumed that pine tar lacks significant carcinogenic activity.23 Further, pine tar used in the manufacture of topical pine tar products available in Australia today has been found not to be carcinogenic by the Ames test (unpublished data, Ego Pharmaceuticals), and is not classified as a carcinogenic.29

Despite the extensive use of medicinal tars, particularly in psoriasis patients, there is no epidemiological evidence that topical tar products, including pine tar, cause cutaneous or internal cancer.24 For example, in a 25-year follow-up study of 280 psoriatic patients treated with coal tar, the investigators concluded that the incidence of cancer had not appreciably increased above the expected incidence in the general population.25 In another study of 719 psoriasis patients, tar therapy (type of tar not indicated) did not increase the incidence of cancer above that expected in the general population over a 10-year period.26,27 Therefore, the apprehension that topical pine tar may be carcinogenic is unfounded, based on the lack of supporting evidence.

Contact allergy

Hypersensitivity reactions for tars are rare, but wood tars are more likely to cause sensitisation than coal tar.7,19 Patch test studies using wood tars have been performed on around 30 000 patients predominately with contact dermatitis.28–31 Wood tars at concentrations of between 5 and 12% generally produced positive reactions in approximately 2–10%28–41 of patients. A small number of studies found positive reactions in 20–50%42–44 of patients. It is important to note that the number of positive reactions for wood tars was not significantly greater than those for other common allergens. In addition, the concentration of pine tar in topical products available in Australia is up to 2.5%, which is up to four times less than that tested in these studies.

Caution must be used when interpreting these types of studies since what is referred to as wood tar in these studies is generally a mixture of pine, juniper, birch and beech tars, and therefore the exact tar eliciting the positive reaction is not known. A positive reaction to pine tar alone would be considerably less as is shown in the study by van Andel and colleagues.52 Of the 650 patients tested, 59 (9%) patients had a positive reaction to wood tar. Of the patients positive for wood tar 55 were available for further testing. Of these, only 20 (60%) were positive to wood tar on renewed testing, and only five (25%), which equals approximately 1% of the original population were positive to pine tar alone. Further, a marked overlap of positive tests to wood tar, coal tar, balsam of Peru, colophony and turpentine was observed, and it was concluded that patch tests with wood and coal tar are of little diagnostic value.52

There has only been one case of adverse reactions to topical products containing pine tar reported in the literature by Iorizzo and colleagues.6 A 61-year-old woman with a 5-year history of vesicular foot eczema presented with an acute dermatitis following the use of pine tar. However, patch testing revealed that she also showed a positive reaction to coal tar, birch tar, beech tar and juniper tar, supporting the finding that these reactions are a consequence of cross-sensitisation and not prior exposure. Her skin lesions rapidly resolved after treatment with topical corticosteroids.6 Furthermore, there have been only five cases of adverse events for pine tar reported to the Therapeutic Goods Administration of Australia since records began in 1971, which included pruritus, rash and dermatitis.

Other adverse effects

Primary irritation is very uncommon, except in unstable psoriasis and treatment on the face, genitalia and the flexures.7,19 An in vitro skin irritancy study has shown that pine tar is a minimal irritant, the lowest on a scale of four categories; minimal, mild, moderate and severe (results unpublished, Ego Pharmaceuticals). Folliculitis is the most common side effect.19 In any case, any adverse effects caused by pine tar are likely to be reduced with the topical products available today, which are generally in contact with the skin for only a relatively short period before being washed off.

CLINICAL STUDIES

Despite the fact that topical pine tar has been used for the treatment of various skin diseases for over 2000 years, few clinical studies on the use of topical pine tar could be found following an extensive literature search conducted...
back to the 1950s. Studies using products containing a mixture of tars, including pine tar, are not included since the results from these studies cannot be attributed to pine tar alone.

In a study by Anderson, 21 patients with generalised chronic dermatoses including psoriasis, mycosis fungoides and eczematous eruptions were treated with a morning bath containing either 5 tablespoons of pine tar or 5 tablespoons of coal tar solutions for 10 min.53 Each patient had 6 consecutive days of one treatment followed by 6 consecutive days of the other. One patient’s skin was irritated by the coal tar bath, and three patients claimed they felt more uncomfortable than before following coal tar baths. None felt this after pine tar baths. Of the 21 patients 19 preferred the pine tar baths due to the attractive green colour and smell. The two who preferred coal tar baths thought the coal tar solution was stronger and did their skin complaint good.55

In a study by Gharavi and colleagues, 50 healthy subjects tested a shampoo containing pine tar.54 A corneocyte count and fungal study showed that pine tar shampoo is effective against pityrosporum ovale. The Draize test and skin sensitisation testing on rabbits used to determine potential irritancy showed that pine tar shampoo is relatively innocuous. In addition, subjects found pine tar shampoo cosmetically acceptable.54

In a further study by Langeveld-Wildschut and colleagues, six patients with atopic eczema were treated with 10% pine tar in cetamacrogol ointment, 0.1% triamcinolone acetonide in cetacamrogl ointment or cetacamrogl ointment vehicle on three separate sites of the back every morning for 5 weeks.55 Atopy patch tests were then performed and biopsy specimens taken for immunohistochemical analysis. Both pine tar and glucocorticosteroid treatments had an almost equally inhibiting effect on the various cellular constituents of allergic inflammation including the influx of T-cells, eosinophils, and CD1+, RFD1+, IFN-γ+, and IL-4+ cells, as well as on the percentage of vessels expressing vascular cell adhesion molecule 1 and E-selectin in response to epicutaneous aeroallergen challenge.55

CONCLUSIONS

Topical pine tar has been used in medicine since antiquity to treat a range of skin conditions, particularly eczema, psoriasis, seborrhoeic dermatitis and other dry, itchy, flaky or inflamed skin conditions, and is still used successfully today.2,7,12,17,18 It is postulated to work by reducing DNA synthesis and mitotic activity, which promotes a return to normal keratinisation. In addition, pine tar is considered to be antiinflammatory, antibacterial and anti-fungal.2,7,12,14,15

In comparison to coal tar, studies have confirmed that the level of PAHs (the constituents of coal tar postulated to cause cancer in humans) in pine tar are very much lower than that found in coal tar.24–27 Furthermore, pine tar has been shown not to be mutagenic.25 Unlike coal tar, pine tar does not cause photosensitisation and is generally in contact with the skin for only a relatively short period before being washed off.10

Only one adverse reaction to topical pine tar in the community was reported in the extensive literature search conducted back to the 1950s.5 Considering the long experience with pine tar therapy and its worldwide usage, the evidence presented in this review suggests that the safety risk from topical pine tar products is very small, while it is useful for treating a wide range of skin conditions.

REFERENCES

1. Al-Asmari A, Siddiqui Y, Mozaffarul I et al. The antibacterial effect of qutran (wood tar) from olive trees on pathogenic bacteria. Int. J. Phytomed. 2014; 6: 444–8.
2. Allen LV Jr. Basics of compounding with tars. Int. J. Pharm. Compd. 2013; 17: 400–10.
3. Muller SA. Topical treatment of psoriasis with tar. Acta Derm. Venerool. Suppl. (Stockh) 1984; 112: 7–10.
4. Paghdal KV, Schwartz RA. Topical tar: back to the future. J. Am. Acad. Dermatol. 2009; 61: 294–502.
5. Ar S, Kargozoglou M, Temel M et al. Traditional tar production from the Anatolian Black Pine (Pinus nigra Arn. subsp. pallasiana [Lamb] Holmboe var. pallasiana) and its usages in Aynkoraharisar, Central Western Turkey. J. Ethnobiol. Ethnomed. 2014; 10: 29–37.
6. Iorizzo M, Lucente P, Pazzaglia M. Allergic contact dermatitis from pine tar. Contact Dermatitis 2000; 43: 125.
7. Sweetman SG (ed.). Martindale: The Complete Drug Reference. 33th edn. London: Pharmaceutical Press, 2007; 1455–4.
8. Braun-Falco O, Plewig G, Wolff HH et al. (eds). Dermatology. Heidelberg: Springer-Verlag, 1991; 1149–50, 1164.
9. Auson AB. Kiln burned pine tar 773 MSDS. [Internet] 2014 [accessed 18 August 2015] Available from URL: http://www. pinetarworld.com/wp-content/uploads/2015/06/KILNBURNEPI NETAR773.pdf
10. Hessel AB, Cruz-Ramon JC, Klinger DM et al. Agents used for treatment of hyperkeratosis. In: Wolverton SE (ed). Comprehensive Dermatologic Drug Therapy, 3rd edn. Philadelphia: Elsevier Health Sciences, 2013; 595–604.
11. Lavker RM, Grove GL, Kilgman AM. The atrophogenic effect of crude coal tar on human epidermis. Br. J. Dermatol. 1981; 105: 77–82.
12. Davther R. Hair care. In: Baran R, Maibach HI (eds). Cosmetic Dermatology. London: Martin Dunitz ; 1994; 117–51.
13. Smith CH, Jackson K, Chinn S et al. A double blind, randomized, controlled clinical trial to assess the efficacy of a new coal tar preparation (Exorex) in the treatment of chronic, plaque type psoriasis. Clin. Exp. Dermatol. 2000; 25: 580–5.
14. Veijola V, Mustakallio E. The bacteriostatic activity of wood tar. Ann. Med. Exp. Biol. Fenn. 1965; 41: 407–14.
15. Ishida H, Nukaya H, Tsuji K et al. Studies on active principles of tars. X. The structures and some reactions of antifungal constituents in PIx Pini. Chem. Pharm. Bull. 1992; 40: 508–15.
16. Fischmeister I, Hellgren L, Vincent J. Infrared spectroscopy for tracing of topically applied ointment vehicles and active substances on healthy skin. Arch. Dermatol. Res. 1975; 255: 65–9.
17. Schmid MH, Korving IIC. Coal tar, pine tar and sulfonated shale oil preparations: Comparative activity, efficacy and safety. Dermatology 1996; 195: 1–5.
18. eMIMS. Pine Tar. [Internet] 2015 [accessed 18 August 2015] Available from URL: http://mims.com.au/index.php/products/ emims.
19. Rook A, Wilkinson DS, Ebling FJG et al. (eds). Textbook of Dermatology, 4th edn. Oxford: Blackwell Scientific, 1986; 1493–4.

© 2016 The Authors. Australasian Journal of Dermatology © 2016 The Australasian College of Dermatologists.
20. Nater JP. Drugs used on the skin. In: Dukes MNG (ed.). Side Effects of Drugs, Annual 5. New York: Elsevier, 1979; 130–7.
21. Swallow WH, Curtis JF. Levels of polycyclic aromatic hydrocarbons in some coal tar skin preparations. *Aust. J. Dermatol.* 1980; 21: 154–7.
22. Ames BN, Mccann J, Yamasaki E. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. *Mutat. Res.* 1975; 31: 547–64.
23. Athanasiou K, Lillis D. Absence of mutagenic and clastogenicity action of pine-tar resin in the Salmonella/microsomal and CHO culture systems. *Mutat. Res.* 1982; 103: 229–52.
24. Gawrkrodger DJ. On behalf of the Therapy Guidelines, Audit Sub-committee of the British Association of Dermatologists. Current management of psoriasis. *J. Dermatol. Treat.* 1997; 8: 27–55.
25. Pittelkow MR, Perry HO, Muller SA *et al.* Skin cancer in patients with psoriasis treated with coal tar. A 25-year follow-up study. *Arch. Dermatol.* 1981; 117: 465–8.
26. Jones SK, MacKie RM, Hole DJ *et al.* Further evidence of the safety of tar in the management of psoriasis. *Br. J. Dermatol.* 1985; 115: 97–101.
27. Jones S, MacKie RM, Hole DJ *et al.* Evidence that topical tar therapy does not cause increased malignancies in psoriatic patients. *Scott. Med. J.* 1984; 29: 260.
28. Agrup G. Hand eczema and other hand dermatoses in south Sweden. *Acta Derm. Venereol.* 1969; 49 (Suppl. 61): 1–91.
29. Bandman HJ, Calnan CD, Cronin E *et al.* Dermatitis from applied medicaments. *Arch. Dermatol.* 1972; 106: 555–7.
30. Fregert S, Hjorth N, Magnusson B *et al.* Epidemiology of contact dermatitis. *Trans. St Johns Hosp. Dermatol. Soc.* 1969; 55: 17–55.
31. Garcia-Perez A, Garcia-Bravo B, Beneit JV. Standard patch tests in agricultural workers. *Contact Dermatitis* 1984; 10: 151–5.
32. Hammershøy O. Standard patch test results in 5,225 consecutive Danish patients from 1975 to 1977. *Contact Dermatitis* 1980; 6: 265–8.
33. Hirano S, Yoshikawa K. Patch testing with European and American standard allergens in Japanese patients. *Contact Dermatitis* 1982; 8: 48–50.
34. Kuljanac I, Knezević E, Cvitanović H. Epicutaneous patch test results in patients with allergic contact dermatitis in Karlovac country – a retrospective survey. *Acta Dermatovenerol. Croat.* 2006; 14: 156–9.
35. Leonard F, Kalis B, Journe F. The standard battery for photopatch tests in France. Prospective study by the French Society for Photodermatology. *Nouv. Dermatol.* 1994;15:505–14.
36. Millard TP, Orton DJ. Changing patterns of contact allergy in chronic inflammatory ear disease. *Contact Dermatitis* 2004; 50: 85–6.
37. Roesyanto ID, van den Akker TW, van Joost TW. Wood tars allergy, cross-sensitization and coal tar. *Contact Dermatitis* 1990; 22: 95–8.
38. van Joost Th, Stolz E, van Der Hoek JCS *et al.* Sensitivity to woodtar. *Contact Dermatitis* 1984; 11: 248.
39. Veien NK, Hattel T, Justesen O *et al.* Patch testing with perfume mixture. *Acta Derm. Venereol.* 1982; 62: 541–5.
40. Veien NK, Hattel T, Justesen O *et al.* Contact dermatitis in children. *Contact Dermatitis* 1982; 8: 755–5.
41. Wereide K. Contact allergy to wool-fat (lanolin). Its incidence in a dermatological in-patient department. *Acta Derm. Venereol.* 1965; 45: 15–8.
42. Fattorini I, Lipozenzei C, Milavec-Puretić V *et al.* Cosmetic dermatitis to neomycin. *Acta Dermatovenerol. Croat.* 1996; 4: 95–9.
43. Saap L, Fahim S, Arsenault E *et al.* Contact sensitivity in patients with leg ulcerations. *Arch. Dermatol.* 2004; 140: 1241–6.
44. Smart V, Alavi A, Coutts P *et al.* Contact allergens in persons with leg ulcers: A Canadian study in contact sensitization. *Int. J. Low Extrem. Wounds* 2008; 7: 120–5.
45. Alomar A, Camarasa JG, Perez AG *et al.* Wood tar patch test. *Contact Dermatitis* 1977; 5: 220.
46. Hölzle E, Neumann N, Haussen B *et al.* Photopatch testing: The 5-year experience of the German, Austrian, and Swiss Photopatch test Group. *J. Am. Acad. Dermatol.* 1991; 25: 59–68.
47. Lamminantausta K, Kalimo K. Do positive nickel reactions increase nonspecific patch test reactivity. *Contact Dermatitis* 1987; 16: 160–5.
48. Magnusson B, Möller H. Contact allergy without skin disease. *Acta Derm. Venereol. Suppl. (Stockh)* 1979; 59 (Suppl. 85): 115–5.
49. Neumann NJ, Hölzle E, Lehmann P *et al.* Pattern analysis of photopatch test reactions. *Photodermatol. Photoinmunol. Photomed.* 1994; 10: 65–75.
50. Young E, Houwing RH. Patch test results with standard allergens over a decade. *Dermatitis* 1987; 17: 104–7.
51. Young E, Van Weelden H, Van deOsch L. Age and sex distribution of the incidence of contact sensitivity to standard allergens. *Contact Dermatitis* 1988; 19: 307–8.
52. van Andel P, Bleumink E, Nater JP. Significance of positive patch tests to wood tars. *Trans. St Johns Hosp. Dermatol. Soc.* 1974; 60: 94–8.
53. Anderson FE. Pinetarsol – a clinical trial. *Aust. J. Dermatol.* 1965; 7: 53.
54. Gharavi M, Momeni S. Formulation of pine tar antidandruff shampoo. Assessment and comparison with some commercial formulations. *J. Sch Pharm Tehran Univ.* 1990;1:145–52.
55. Langeveld-Wildschut EG, Riedl H, Thepen T *et al.* Modulation of the atopy patch test reaction by topical corticosteroids and tar. *J. Allergy Clin. Immunol.* 2000; 106: 757–45.

© 2016 The Authors. *Australasian Journal of Dermatology* © 2016 The Australasian College of Dermatologists.